Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Sponsor: TORL Biotherapeutics, LLC
Summary
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Official title: A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
155
Start Date
2026-03-31
Completion Date
2029-09-30
Last Updated
2026-06-11
Healthy Volunteers
No
Interventions
TORL-5-700
Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks
TORL-5-700 at MTD/RP2D
Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks
TORL-5-700 at MTD/RP2D in combination with another agent
Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent
Locations (3)
UCLA
Santa Monica, California, United States
Stanford University
Stanford, California, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States